Search

everythinglearnresearchcommunity

for

Search:↓

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.

Sorafenib may cause hair loss in a way similar to alopecia areata.

Activated ras can protect kidney cells from a certain substance that causes cell death.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Imuvert can prevent some chemotherapy-induced hair loss.

VHL disease can cause early paragangliomas, needing lifelong monitoring.

Vinblastine can help treat childhood ITP but may cause reversible side effects.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.

Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.

MVP treatment is effective and safe for recurrent breast cancer.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

AS101 reduces hair loss from chemotherapy.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

The treatment is safe and shows promise for metastatic breast cancer.

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.

Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.

Sorafenib can cause a temporary skin condition that goes away after stopping the drug.

Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.